Latest News

RCC: Computer-assisted Tumor Response Reduces Evaluation Errors

RCC: Computer-assisted Tumor Response Reduces Evaluation Errors

Computer-assisted evaluation of tumor response reduced errors and time of evaluation compared with standard-of-care.

Cryoablation May Offer Oncologic Control in cT1 Solitary Renal Masses

Cryoablation May Offer Oncologic Control in cT1 Solitary Renal Masses

Cryoablation was associated with good short-term oncologic control and an excellent safety profile in "healthier" patients.

Genetic Conditions and Renal Cell Carcinoma

Genetic Conditions and Renal Cell Carcinoma

The understanding of genetic conditions with predisposition to renal cell cancer is critical for developing better therapies.

Efficacy of Osimertinib in Advanced T790M-positive NSCLC

Efficacy of Osimertinib in Advanced T790M-positive NSCLC

Osimertinib confers a high overall response rate and encouraging progression-free survival among patients with non-small cell lung cancer (NSCLC).

Hormonal Maintenance May Improve PFS in Low-grade Ovarian Cancer

Hormonal Maintenance May Improve PFS in Low-grade Ovarian Cancer

Hormonal maintenance therapy after primary treatment significantly prolonged progression-free survival compared with observation,

Hodgkin Lymphoma: Intensifying Treatment With Rituximab After PET

Hodgkin Lymphoma: Intensifying Treatment With Rituximab After PET

Adjusting treatment dose after 2 courses of first-line therapy based on a positive PET scan does not improve progression-free survival.

First-line Immune Checkpoint Inhibition Cost-effective in Melanoma

First-line Immune Checkpoint Inhibition Cost-effective in Melanoma

First-line immune checkpoint inhibition is more cost-effective than chemotherapy for treatment-naïve, BRAF wild-type, stage IV melanoma.

Olaparib Improves PFS in BRCA-mutant Breast Cancer

Olaparib Improves PFS in BRCA-mutant Breast Cancer

Olaparib significantly prolonged progression-free survival compared with chemotherapy among patients with HER2-negative breast cancer.

Nivolumab Active in Squamous Cell Carcinoma of the Anal Canal

Nivolumab Active in Squamous Cell Carcinoma of the Anal Canal

Nivolumab was clinically active and well-tolerated among patients with treatment-refractory metastatic squamous cell carcinoma of the anal canal (SCCA).

Cyclophosphamide Reduction in Rhabdomyosarcoma

Cyclophosphamide Reduction in Rhabdomyosarcoma

Reducing the cyclophosphamide dose for a subset of patients with rhabdomyosarcoma may increase the risk of disease recurrence.

Safety of Active Surveillance for Small Renal Masses

Safety of Active Surveillance for Small Renal Masses

Active surveillance appears to be a safe alternative to primary intervention for selected patients with small renal masses.

Dual Immunotherapy Active vs Sunitinib for PD-L1+ Advanced RCC

Dual Immunotherapy Active vs Sunitinib for PD-L1+ Advanced RCC

Atezolizumab (Tecentriq) combined with bevacizumab (Avastin) demonstrated antitumor activity compared with sunitinib as first-line therapy.

Genomic Alterations in Metastatic Renal Cell Carcinoma

Genomic Alterations in Metastatic Renal Cell Carcinoma

Patients with metastatic renal carcinoma (mRCC) treated with post-frontline agents had increased genomic alterations.

Adjuvant BEP for 1 Cycle Safe, Efficacious for Testicular Cancer

Adjuvant BEP for 1 Cycle Safe, Efficacious for Testicular Cancer

Bleomycin, etoposide, and cisplatin (BEP) for 1 cycle after orchiectomy is associated with a similar 2-year recurrence rate as BEP.

Urothelial Carcinoma: Year in Review

Urothelial Carcinoma: Year in Review

Studies presented in the last year demonstrated a revolutionary role for immune checkpoint inhibitors.

Pembrolizumab Improves Survival and Quality of Life in Advanced Bladder Cancer

Pembrolizumab Improves Survival and Quality of Life in Advanced Bladder Cancer

Pembrolizumab following platinum-based chemotherapy was associated with significantly longer overall survival, fewer adverse events.

Bladder Cancer: Genomics May Predict Benefit from Neoadjuvant Chemotherapy

Bladder Cancer: Genomics May Predict Benefit from Neoadjuvant Chemotherapy

David J. McConkey, MD, PhD, described how genomics can affect the clinical management of patients with bladder cancer.

Bladder Cancer: Neoadjuvant Chemotherapy and Molecular Subtype

Bladder Cancer: Neoadjuvant Chemotherapy and Molecular Subtype

The clinical outcomes when using neoadjuvant chemotherapy for muscle-invasive bladder cancer vary by molecular subtype.

Chemo + Radiotherapy Efficacious in Muscle-invasive Bladder Cancer

Chemo + Radiotherapy Efficacious in Muscle-invasive Bladder Cancer

Adding chemotherapy with fluorouracil and mitomycin to radiotherapy improves locoregional control.

mCRPC: Full-length AR Copy Number Prognostic for Outcomes

mCRPC: Full-length AR Copy Number Prognostic for Outcomes

Full-length androgen receptor (AR-FL) copy number derived from circulating tumor cells detected using a liquid biopsy.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters